Ascletis Pharmaceutical, Clover and other B-class pharmaceutical stocks strengthened

On the afternoon of December 20, Hong Kong pharmaceutical stocks diverged, with some Class B pharmaceutical stocks strengthening, Ascletis Pharmaceutical-B rose by more than 35%, and Clover-B rose by more than 14%.

In addition, CanSino Biologics followed suit
.
On the afternoon of December 20, Hong Kong stock Ascletis Pharmaceutical rose more than 35%
in the afternoon.
Meanwhile, the company's share price has continued to rise since the end of October and has now reached a seven-month high
.
On the news, Ascletis announced that patent and use patent application for oral viral polymerase inhibitor ASC10 and derivatives for the treatment of monkeypox virus and human respiratory syncytial virus (RSV) and other viral infections have received a notice of grant from the United States Patent and Trademark Office (USPTO
).
It is reported that ASC10 is independently developed by Ascletis Pharmaceutical, is an oral double prodrug, after oral administration, ASC10 and monolavir can be quickly converted to the same active drug ASC10-A
in vivo.
In addition, in the hepatitis B market, Ascletis is used for the functional cure
of chronic hepatitis B by blocking the PD-1/PD-L1 signaling pathway.
ASC22 R&D has entered the IIb expansion phase and is expected to release new clinical data
in the second half of 2023.
The company also lays out the NASH field
of tens of billions of blue oceans.
According to the R&D progress announced by the company, while consolidating the basic antiviral plate, a total of a number of pipelines are expected to submit marketing applications from 2023 to 2024, covering acne, functional cure of hepatitis B, primary biliary cholangitis, recurrent glioblastoma and other subdivisions
.
On the afternoon of December 20, Clover-B rose more than 14%.

On the news, Goldman Sachs Research reported that based on Clover's latest allotment, the bank fine-tuned its 2022/23/24 net profit forecast by +0.
9%/0.
6%/-0.
7% to reflect the change
in net cash.
At the same time, the company's valuation based on discounted cash flow was extended for three months, so the target price was raised by 3% from HK$3.
26 to HK$
3.
37.
The bank's investment views and ratings were unchanged and maintained a "neutral" rating
.
According to the bank, Clover's main upside factors include: 1) better than expected sales share and pricing in the Chinese market; 2) higher long-term penetration of vaccines; 3) Better than expected commercialization
.
In addition, the company recently responded to the production of viral vaccines by saying that the annual peak production capacity of its recombinant viral protein subvaccine (CHO cells) is expected to reach hundreds of millions of doses
.
According to the data, Clover is a biotechnology company in the clinical trial stage, committed to developing novel vaccine and biotherapeutic product candidates for infectious diseases, cancer and autoimmune diseases
.
The core products are SCB-2019, and SCB-808
for the treatment of rheumatic diseases.
In the future, the company will continue to leverage its mature independent R&D capabilities and Trimer-TagTM technology, as well as successful international cooperation experience, to establish an innovative and potential vaccine portfolio
.
This includes the continued development of trimeric vaccines, SCB-2020S and SCB-1001 (rabies G-Trimer vaccine).

As of June 30, 2022, the Company had approximately US$336 million (RMB2,256 million) in cash and cash equivalents
.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.